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FIGURE S1
The chemotaxis of T cells to recombinant CTACK. PBL that had migrated were labelled with florescent antibodies to T-cell marker CD3, memory cell marker CD45RO and "skin-homing" marker CLA. % migration is the normalised chemotaxis of (a) CD3+CD45RO+ cells or (b) CD3+CD45RO+CLA+ compared to the number of specific input cells to 50, 100 or 150 ng of CTACK (ctack 50, ctack 100 and ctack 150 respectively). Basal migration is the migration of cells to cell culture medium only. * represents a significant increase in the % migration (P < .05) compared to basal migration performed by allele-specific PCR (codon 600) and DNA sequencing (exon 15) as detailed. [7, 8] The search for mutations in NRAS (exons 2 and 3) and in KIT (exons 11, 13 and 17) was performed by direct DNA sequencing.
[9]
| RESULTS
Of the 27 patients who had presented a melanoma of the female lower genital tract since 2003, 22 had available samples for mutations screening. These samples came from the primary melanoma and/or metastases.
The main clinical and pathological features of these 22 patients are summarized in Table 1 ).
Ten of the 22 patients had several distinct samples available for mutation screening (from the primary melanoma or/and metastases): 6 patients had 2 samples and 4 patients had 3 samples available. Nine of these 10 patients with multiple tests had concordant mutation status results from one sample to another ( Table 2) . One patient (case 5), who was previously tested negative on the primary melanoma, had a NRAS mutation in a cutaneous metastasis.
| CONCLUSIONS
Data concerning the mutational pattern in vulvar and vaginal melanomas are scarce. Fourteen studies describing such data were found in the literature (Table S1 ).
Our observed mutational pattern was different from most of these previous studies. Indeed, we demonstrated a BRAF mutation rate of 22.6% in our population, which was much higher than the rate of 5%
observed by Tseng et al [3] in their systematic review (10 studies). One possible explanation is that we used a more sensitive technique. Our data are in agreement with those recently reported by Hou et al [10] T A B L E 1 Clinical and pathological data of the 22 patients with vulvar or vaginal melanomas with a BRAF mutation rate of 26%. They also used a sensitive approach based on next-generation sequencing. However, we only detected BRAF V600E mutations in our series. This result underlines potential additional opportunities for targeted therapies in these patients.
Similarly, although a high CKIT mutation prevalence was previously described in vulvo-vaginal melanomas (26%), a lower prevalence was observed in our study (9.1%). In order to rule out that this was not related to a lack of sensitivity of the technique used, the available samples (n = 20) were retested using a PCR-based assay that uses allelespecific primers to identify the presence of somatic mutations in KIT (Entrogen, Woodland Hills, CA, USA). This sensitive technique (limit of detection below 5%) did not allow us to detect any additional mutation. Our observed rate of NRAS mutation was comparable to those previously shown in other studies (15%). Concerning the mutational pattern according to melanomas localizations, no clear difference between vulvar and vaginal melanomas has previously been reported in the literature (Table S1 ). In our study, BRAF mutation was exclusively identified in vulvar melanoma cases (33.3% of vulvar melanoma cases)
whereas NRAS was only detected in 42.8% of vaginal melanomas (P = .023). Finally, our discovery of a discordant mutational pattern (case 5) highlights the fact that the absence of mutation in a particular sample should not be taken as a definitive result. This kind of evolution has already been described for cutaneous melanomas for which BRAF discordant status between 2 distinct samples can be found. [7] To our knowledge, our discordant mutational status of female lower genital tract melanoma is the first described in the literature. To conclude, our study demonstrates a higher rate of BRAF mutation in vulvar melanomas than previously demonstrated in the literature. It is of main
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